ATW SPAC Management’s Cardio Diagnostics CDIO Stock Holding History

ATW SPAC Management’s Portfolio CDIO Stock Details CDIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-452	Closed	-$14.4K	–	186
2022 Q4	$14.4K	Sell	452 -7,548	-94%	-$815K	﹤0.01%	152
2022 Q3	$2.41M	Hold	8,000	–	–	0.38%	102
2022 Q2	$2.39M	Hold	8,000	–	–	0.34%	107
2022 Q1	$2.37M	Buy	+8,000	New	+$2.36M	0.32%	103

Other funds holding CDIO

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

CSC

Caldwell Sutter Capital Sausalito, California $265M AUM 30.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

ATW SPAC Management's CDIO Position: Q1 2023 in Review

ATW SPAC Management sold out of Cardio Diagnostics (CDIO) in Q1 2023, closing a stake of 452 shares — an estimated $14.4K sold.

ATW SPAC Management first reported a position in CDIO in Q1 2022 and held it in 4 quarters. The position peaked at $2.41M in Q3 2022. 11 funds tracked by Wall St. Rank hold CDIO as of Q1 2023.

ATW SPAC Management reported no remaining Cardio Diagnostics position as of Q1 2023 after selling out during the quarter.
ATW SPAC Management sold 452 Cardio Diagnostics shares in Q1 2023, an estimated $14.4K.
ATW SPAC Management first reported a position in Cardio Diagnostics in Q1 2022 and held it in 4 quarters.
ATW SPAC Management's Cardio Diagnostics position peaked at $2.41M in Q3 2022.
11 funds tracked by Wall St. Rank held Cardio Diagnostics as of Q1 2023.

Based on ATW SPAC Management's 13F filing for Q1 2023, filed 15 May 2023.